| Meta Information | Value |
|---|---|
| Rating | Neutral |
| Target price range | HK$29–32.5 per share (base-case rNPV/SOTP fair value) |
| Current price | HK$27.02 (close on 2026-11-06, valuation reference price for this report) |
| Margin of safety | Approximately +7.3% (base-case fair value floor of HK$29 vs. current price) |
| Time horizon | 12 months |
| Market capitalization | Approximately HK$9.578 billion (approximately RMB 8.15 billion) |
| Report date | 2026-11-07 |
Everest Medicines is a leading "non-oncology differentiated" Biotech among Hong Kong 18A names in terms of delivery: Nefecon, following its inclusion in the National Reimbursement Drug List (NRDL), has driven revenue to more than double for two consecutive years (FY2025 +141.5%, 2026H1 +157.3%), adjusted results have turned positive, 8 assets have entered commercialization or late-stage registration, and an upfront payment of USD 112.5 million from the out-licensing of EVER001 was received in July 2026. However, this report assigns a Neutral/Watch rating for the following reasons: First, the current price of HK$27.02 represents a discount of only about 14% to our in-house base-case fair value of HK$30.8, providing a margin of safety of less than 10%; Second, Nefecon accounted for approximately 77% of 2026H1 revenue, and in 2027, NRDL renewal price cuts combined with the market entry of multiple competing products such as atrasentan and telitacicept create a quantifiable downside scenario of a "price + share" double hit (bear case: HK$11.5–13.5); Third, reported profitability is highly dependent on one-off items (fair value gains, deferred tax assets), and operating cash flow remained negative at RMB -273 million in 2026H1. The next 6 months feature a dense event calendar (EGM on 11-16, NRDL negotiation results in late November, Xiwentuo launch, and the 2027-03 annual report validating Nefecon guidance of RMB 2.4–2.6 billion); risk-reward is unattractive ahead of validation milestones, and we recommend awaiting the NRDL outcomes and H2 volume data before making a directional decision.
Market environment: The Hong Kong innovative drug sector is in a post-rally earnings validation period following the substantial gains of 2025. Everest's current price sits at the 15.7th percentile of its 52-week range (HK$22.70–50.30), a drawdown of approximately 46% from the 52-week high — though it should be noted that this high was partly shaped by the mRNA sector sentiment spike on August 20 (a single-day gain of +41.4%), limiting the reference value of the low percentile. Event-day volatility has been extreme (August 19: -18.7%; August 20: +41.4%), indicating a strong event-driven trading profile.
The three developments most likely to move the share price over the next 6–12 months: ① 2026 NRDL negotiation results (announced in late November): Wezina (vericiguat?) and Xeglyze competing for new listings, Nefecon renewal within the formulary — directly determining whether the "multi-product relay" narrative for 2027 holds; ② Nefecon's H2 ramp toward the RMB 2.4–2.6 billion guidance: H1 delivered only RMB 889 million (revenue basis), implying H2 needs RMB 1.51–1.71 billion, or +70–93% quarter-on-quarter — the core variable for the base-case scenario (peak sales of RMB 3.8 billion); ③ Competitor listing cadence: telitacicept's IgAN indication has been approved and qualifies for the 2026 NRDL negotiations; if successful in November, it could begin diverting patients from 2027-01-01, moving the impact one year earlier than the market's default assumption of "2027–2028."
Expectation gaps: The sell-side 12-month consensus target price averages approximately HK$40.5 (BOCOM: 66; SDIC: 43.82; CICC: 41.5; range HK$25.94–67.68; 3 Buys, 0 Sells), with the current price at a 33–59% discount; however, this anchor has been in a systematic downward revision channel since September 2025 (BOCOM 84→66; CICC 88→41.5) and warrants a discount when referenced. Our in-house base case (HK$30.8) differs from the current price by only +14%, a low-divergence zone — we do not argue the market is broadly wrong; only that the market's roughly half-price treatment of the second-tier assets (Xiwentuo/Wezina/EVER001) is largely fair, while the pricing range for Nefecon's peak sales (RMB 2.8–5.0 billion) is too wide, with the direction of convergence dependent on the NRDL outcome. Evidence strength is moderate — core financials are sourced from company announcements, but Nefecon's product-level revenue and competitor prescription data rely on sell-side/media reports.
Primary catalysts and falsification conditions: Catalysts — successful NRDL negotiations (+10–20%), EGM approval (neutral-to-positive), Xiwentuo launch and ramp-up (+5–10%), Leruvab approval (2027Q2, +5–10%); Falsification — Nefecon renewal price cut exceeding 30%, FY2026 Nefecon sales below the RMB 2.4 billion floor, EGM rejection, and operating cash flow failing to turn positive in 2027.
Revenue grew from RMB 126 million (FY2023) to RMB 707 million (FY2024) to RMB 1.707 billion (FY2025) (+461%, then +141.5%); 2026H1 reached RMB 1.148 billion (+157.3%), of which pharmaceutical product sales were RMB 1.003 billion (+124.8%) and Haisen CSO service fees were RMB 145 million. Nefecon's 2026H1 sales revenue was approximately RMB 889 million (revenue basis, vs. approximately RMB 303 million in 2025H1, up roughly +193% year-over-year; on the company's net sales basis, growth was +94% year-over-year—the two bases are not interchangeable). It should be noted that the company guides FY2026 Nefecon sales of RMB 2.4-2.6 billion, implying H2 needs RMB 1.51-1.71 billion, or +70-93% sequentially (+33-50% year-over-year); moreover, telitacicept has been on sale since June 2026 and the NRDL negotiation results will not be announced until late November, leaving renewal unresolved for most of H2—meeting the guidance is a "to-be-verified execution target" rather than a fait accompli. The concentrated H2 ramp-up in 2025 after capacity approval (approximately +275% sequentially) offers precedent, but the headwinds in 2026 are structurally different. Accounting bases must be stated precisely: in 2026H1 the company remained loss-making on an attributable-to-parent basis at RMB 5.94 million, while adjusted profit was +RMB 97 million; this report estimates recurring losses at approximately RMB 65 million.
Xingbituo (星必妥) is the only out-of-hospital self-rescue therapy for acute PSVT episodes in China (patient population approximately 3-6 million; global Phase III 30-minute conversion rate 64% vs. 31% for placebo), but since approval there has been no pricing or stocking/distribution data; with as-needed dosing and full out-of-pocket payment in the early launch period, both the real annual treated population and revenue per patient are unverified. The volume ramp for Weishiping (UC; approved February 2026) and Yijia is contingent on successful NRDL negotiations, the results of which have not been announced. The BLA for Leruibo (乐瑞泊; PCSK9) has been accepted, but China already has five approved PCSK9 monoclonal antibodies as well as inclisiran, most of which are already NRDL-covered—a red-ocean late entrant. The EVER001 upfront payment of USD 112.5 million (approximately RMB 750 million) is a one-time monetization of rights with no equivalent follow-on in 2027, and its recognition timing (one-time vs. deferred) will distort FY2026/FY2027 year-over-year comparability. Conclusion: the strategic direction is sound but the pace is uncertain; the 2027-2028 succession of volume drivers must be validated item by item, and extrapolating linearly from approval events alone is not advisable.
The IgA nephropathy space has moved from blue ocean to intense competition: five products are approved globally (Nefecon, sparsentan, Iptacopan, atrasentan, and sibeprenlimab); in China, telitacicept received conditional approval in June 2026, iptacopan and atrasentan are on the market, and Zai Lab's povetacicept has shown positive Phase III data. Atrasentan's listed price of RMB 6,658 per box establishes a price anchor—both providing the NRDL authority with an in-class reference and directly competing for prescriptions. Nefecon accounted for approximately 77% of 2026H1 revenue and approximately 89% of pharmaceutical product sales, so the single-product structure amplifies any share diversion. Two points warrant clarification: the Hainan Herui budesonide enteric-coated first generic has been internalized by the company as its own commercialized collaboration product (channel coexistence rather than a pure threat); and telitacicept is injectable with confirmatory endpoints not yet read out, so the pace of diversion may be slower than feared—however, if it succeeds in the November 2026 NRDL negotiations, the impact would materialize earlier, from January 1, 2027; this is one of the triggers for this report's bear case. Additionally, the CSPC budesonide enteric-coated competing product is based on sell-side/media reports, and its approval details remain to be verified.
Of the FY2025 adjusted profit of RMB187 million, RMB300 million consisted of a one-off deferred tax asset recognition (approximately -RMB113 million excluding it); of the 2026H1 adjusted profit of RMB97 million, RMB89 million was attributable to fair value remeasurement of the Hygeia equity stake (91.6%), and the DTA recognized in FY2025 was utilized in 2026H1, converting into income tax expense of RMB30.33 million — reliance of the "earnings inflection" narrative on one-off items appears systematic. On the cash side: 2026H1 operating cash flow was -RMB273 million, mainly due to working capital absorption from accounts receivable (+RMB128 million), inventory (+RMB57 million), and a decrease in accounts payable (RMB152 million), a combined drag of RMB368 million — two readings coexist: growth-driven working capital absorption under +157% revenue growth vs. collection quality concerns (all receivables within 3 months; impairment of only RMB92,000, supporting the former). Net cash position is caliber-sensitive: cash of RMB1.859 billion + July EVER001 upfront payment of RMB750 million - interest-bearing borrowings of RMB1.921 billion - Hygeia remaining payment of approximately RMB650 million ≈ +RMB40 million; excluding the remaining payment, approximately +RMB690 million. Impairments in three consecutive years (RMB52/356/312 million) indicate that the sunk cost of BD upfront payment discipline is not low.
The transaction exposure between the CBC-affiliated entities controlled by Fu Wei (holding 25.27% through trusts) and the Company has expanded rapidly: the acquisition of Hygeia Healthcare (Singapore) for US$250 million plus assumption of shareholder loans of US$148.8 million added goodwill of RMB651 million; procurement caps from Hygeia for 2026/27/28 are RMB356/2,215/3,076 million (a jump of approximately 5.2x in 2027 versus 2026); reverse service fee caps are RMB560/616/677 million, with net exposure of approximately RMB1,600/2,400 million in 2027/2028; an independent shareholders' vote at the EGM on 11-16 (CBC-affiliated parties abstaining). The offsetting factor is CBC/management share purchases — but this must be stated precisely: the average purchase price was approximately HK$33.4 per share, with the current price at an approximately 19% discount to their cost (paper losses on the purchasing parties' positions); the most recent purchase (2026-06) was executed at HK$26.99, below the current price. The purchasing parties are precisely the driving parties behind the related-party transactions; their signal value cannot be distinguished from the "self-reinforcing interest alignment" hypothesis and should be interpreted with a discount. On 11-03, the share price fell 6.3% on the day of the Hygeia related-party news, indicating the market is already pricing this in.
The in-house rNPV/SOTP base case is HKD 30.8 per share; the current price of 27.02 represents a discount of approximately 14%. Relative to sell-side anchors (HKD 40.5–66), the discount is 33–59%; however, sell-side anchors are on a downward revision trajectory, and all their target prices predate the competitive events of October–November, so the apparent undervaluation may be compressed in the same direction. Relative valuation: PS (FY2025) of 4.78x, roughly 53% below the median of approximately 10.1x among four peers (Innovent 9.85x / RemeGen 10.38x / Akeso 22.35x / Zai Lab 6.37x) — though this discount partly reflects genuine structural factors: single-product concentration (approximately 89% of pharmaceutical revenue from Nefecon), a single distributor accounting for 98%, and FY2026 revenue including approximately RMB 750 million in one-time licensing payments. The denominator of the PB ratio of 1.56x is compressed by accumulated losses (approximately RMB 10.56 billion), limiting its cross-comparison value. Reverse-solving the current price implies a valuation of approximately "Nefecon peak of RMB 2.8–5.0 billion plus second-line pipeline at a 50–90% discount," with essentially zero premium for the mRNA platform. Confidence in this judgment is low (0.50): shifting the Nefecon peak from RMB 3.8 billion to RMB 2.2 billion or RMB 5.0 billion moves the fair value from HKD 30.8 to HKD 12.6 or HKD 56.2 — the valuation conclusion is essentially a function of the peak sales assumption.
| Metric | FY2023 | FY2024 | FY2025 | 2026H1 (latest period) |
|---|---|---|---|---|
| Revenue | 1.26 | 7.07 | 17.07 | 11.48 |
| YoY | — | +461.2% | +141.5% | +157.3% |
| Net profit attributable to shareholders of the parent | -8.45 | -10.41 | -2.98 | -0.06 |
| Adjusted profit (company definition, excluding SBC and amortization of intangible assets) | — | — | +1.87 | +0.97 |
| Recurring net profit (this report's estimate, also excluding non-recurring gains and losses) | — | — | -3.64 | -0.65 |
| Gross margin | 72.7% | 74.6% | 69.3% | 69.6% |
| Net margin | -670%* | -147%* | -17.5% | -0.5% |
| R&D expenses | 5.40 | 5.28 | 5.11 | 2.56 |
| Distribution and selling expenses | 2.31 | 5.08 | 7.81 | 4.58 |
| Operating cash flow | -7.69 | -6.80 | -0.93 | -2.73 |
| Free cash flow (estimate: OCF minus purchases and construction of fixed assets) | -8.86 | -7.45 | -1.57 | -3.31 |
| Cash and bank deposits (period-end) | 23.50 | 16.03 | 27.32 | 18.59 (2026-06-30) |
| Cash-like assets (financial assets at FVTPL) | — | — | — | 1.77 |
| Interest-bearing borrowings | 0.23 | ≈0 | 8.67 | 19.21 |
| Liabilities-to-assets ratio | — | — | 22.4% | 38.1% |
*Revenue bases were small in the early years, distorting net-margin ratios; these figures are provided only as a directional reference. Net debt/EBITDA is not applicable because EBITDA is close to zero. Also, the net HKD 1,553 million raised through the 2025-08 placement is already included in year-end 2025 cash; the approximately RMB 750 million EVER001 upfront payment received in 2026-07 is excluded from the table above as a subsequent event.
Reasons for changes in metrics (items with YoY changes of at least ±20%, with management explanations): FY2024 revenue +461%—contributions from the first full year following Nefecon's launch in May 2024 and launches in new markets in Hong Kong and Taiwan; FY2025 revenue +141.5%—the company cited "Nefecon®'s inclusion in the National Reimbursement Drug List (NRDL) as a key growth driver," supplemented by launches in Taiwan, South Korea and Singapore; FY2025 gross margin -5.3pp—Nefecon's reimbursement price took effect in January 2025, with the company using "process improvements and supply-chain streamlining ... joint cost-reduction programs" to offset the impact; 2026H1 revenue +157.3%—Nefecon's volume ramp-up plus consolidation of Haisen's (海森) CSO business (RMB 145 million); FY2025 net loss attributable to shareholders of the parent narrowed by 71.4%—management attributed this to four factors: product revenue growth, operating efficiency, recognition of RMB 301 million in deferred tax assets on Singapore tax losses, and RMB 312 million in pipeline impairment; 2026H1 borrowings +121.7% to RMB 1,921 million—the Haisen acquisition, completed in June with a net cash outflow of RMB 1,004 million, was financed through bank borrowings, with the loans secured by EverSea equity; inventories +369.7% to RMB 151 million—the company did not explain this change; a reasonable inference is inventory buildup for new launches (维适平, 星必妥 and the consolidation of Haisen's 14 products).
Revenue of RMB1,148 million (+157.3%) reached a record half-year high, comprising pharmaceutical sales of RMB1,003 million (+124.8%), Nefecon of approximately RMB889 million (up approximately +193% YoY on a revenue basis, +94% on a net sales basis), and CSO service fees of RMB145 million (new, 12.6% of revenue); gross margin of 69.6% (+2.5pp YoY, reflecting the effectiveness of cost-reduction initiatives); loss attributable to shareholders narrowed to RMB5.94 million, while adjusted profit was +RMB97 million—however, 91.6% of the latter derived from fair-value remeasurement of the listed equity stake in Micurt (麦科奥特); after excluding this, recurring results were approximately -RMB65 million, a substantial improvement versus 2025H1 (-RMB250 million) but not yet genuinely positive. The market reaction was negative: the share price fell -18.7% on the first day after results, and BOCOM International subsequently cut its 2026-28 revenue forecasts by 15-18% (mainly due to generic competition for Nefecon and tight overseas CDMO supply of Yijia, with roughly RMB150 million of shipments deferred from H1)—as no publicly available H1 consensus detail exists, this report does not draw firm conclusions on "beat/miss"; anchored on management guidance: Nefecon completed 37% of the lower bound of the RMB2.4 billion guidance in H1, requiring RMB1.51-1.71 billion in H2 (+70-93% QoQ), which will be challenging to achieve. The balance sheet was restructured by the Hansen acquisition: goodwill of +RMB651 million (recognized for the first time), intangible assets up +63% to RMB3,412 million, borrowings up +121.7% to RMB1,921 million, and net cash of approximately +RMB40 million (including the July upfront payment).
Business model: A three-tier structure of license-in plus in-house commercialization plus an in-house mRNA platform. It is an asset-light pharmaceutical model (low CapEx intensity at the Jiashan plant: FY2025 purchases of fixed assets of RMB64 million vs. depreciation of RMB157 million, CapEx/depreciation of only 0.41); the true capital commitment lies in licensed intangible assets (RMB284 million purchased in FY2025 and RMB448 million in 2026H1). Revenue shows low recurrence: pharmaceutical sales scale in steps with NRDL (medical insurance) inclusion, CSO service fees are related-party contractual revenue (20-55% revenue-share rates), and one-off licensing payments (EVER001, RMB750 million) are not sustainable. Pricing power is weak: NRDL entry entails price cuts (gross margin -5.3pp), with volume offsetting price.
Cash conversion of earnings: OCF/net profit series of 0.91 (2023) → 0.65 (2024) → 0.31 (2025) → with profit near breakeven while OCF was still -RMB273 million (2026H1)—conversion of book profit into cash deteriorated and has not since converged, mainly because working capital expanded with revenue up +157% (receivables/inventory/payables combined a drag of RMB368 million); FCF for 2026H1 was -RMB331 million (excluding the RMB448 million in license payments, total cash consumption is larger). Recurring profitability test: the gap between adjusted profit and attributable/recurring measures is ≥±15% and consistently in a "flattering" direction—FY2025 adjusted +RMB187 million vs. estimated recurring -RMB364 million, a difference of RMB550 million (DTA +RMB300 million, impairment add-backs, etc.); the company's own reported basis adds back all SBC (FY2025 RMB132 million, 7.7% of revenue) and intangible amortization, which is a relatively loose measure.
Return on capital: On a recurring basis the company remains loss-making, so ROIC is negative and not meaningful; by industry comparison, profitable biotechs (Innovent, ROE 5%) have only just crossed the capital-return threshold—Genting is at the "eve of profitability" rather than the "moat realization" stage.
Moats and red flags: The moat lies in channel and market-access execution (coverage of 1,900 hospitals, access capability demonstrated by NRDL negotiation in the first year of launch, and the Kangqiao BD network), rather than in the molecules themselves (all core products are license-in, with patents held by the licensors). Red flags: the single distributor Keyuan Xinhai accounts for approximately 98% of revenue and the top five customers for 99.9% (extremely high channel concentration, without special explanation from the company); intangible assets plus goodwill represent 48.1% of total assets; impairments for three consecutive years; ongoing SBC dilution (2026 share scheme authorization cap of 10%).
Consistency between words and actions: pragmatic, with strong execution. Three sets of commitments versus delivery: (1) the FY2023 annual report's outlook for 2024—Nefecon launches in Taiwan and South Korea, full NMPA approval, inclusion in the KDIGO 2025 guideline, Hong Kong approval of Weishiping (维适平), and one-year follow-up data for EVER001—was fulfilled through full approval in May 2025, capacity-expansion approval in August, inclusion in KDIGO 2025, launches in Taiwan and South Korea, Hong Kong approval in April, and disclosure of 52-week data at ERA 2025: all were delivered; (2) FY2026 Nefecon guidance of RMB 2.4-2.6 billion remains in progress, with 37% achieved in H1; (3) the 2025 commitments to submit the BLA for Leruibo (乐瑞泊) in H1 and obtain approval for Xingbituo (星必妥) within the year were fulfilled: Leruibo's application was accepted in June ("achieved on schedule as planned"), and Xingbituo was approved on September 3. The only delay was EVM14 dose escalation, postponed to 2027Q1. Revenue guidance for 2023 was RMB 70-100 million, versus actual revenue of RMB 126 million, exceeding guidance.
Shareholder friendliness: neutral, with a bias toward raising capital. There have been no dividends or buybacks since listing. In 2025-08, a top-up placement of 22.56 million shares at HKD 69.7 (158% above the current price) raised net proceeds of HKD 1.553 billion and diluted shareholders by approximately 6.4%. The share price now being far below the placement price indicates that the financing timing was unfavorable to existing shareholders. A positive signal is that Kangqiao (康桥)/management have purchased 5.163 million additional shares since 2025-12, at an average price of approximately HKD 33.4; the current price is approximately 19% below their cost.
Risk signals: (1) the auditor changed from PricewaterhouseCoopers to EY in 2024-11, with no public statement of disagreement; this warrants attention; (2) transactions with the controlling shareholder's Kangqiao group have risen sharply (see C5), and the EGM circular itself acknowledges "increased transaction concentration and counterparty risk with the Haisen group"; (3) the 2030 revenue target of RMB 15 billion—8.8 times FY2025 revenue, implying approximately 54% CAGR over 2025-2030—is ambitious, while management ceased providing full-year revenue guidance in 2026 and positioned it as a "year of execution"; the narrowing of guidance itself deserves attention; (4) the change in a non-executive director in 2026-08 and establishment of an ESG committee are routine governance actions.
| Segment/product | Share of 2026H1 revenue | Gross margin | YoY | Business logic in one sentence |
|---|---|---|---|---|
| Nefecon (enteric-coated budesonide, IgA nephropathy) | Approximately 77% (RMB 889 million) | Not separately disclosed (69.6% overall) | Approximately +193% on a revenue basis | The only fully approved disease-targeted IgAN drug; second-year reimbursement-driven volume growth offsets price reductions |
| Yijia (依嘉; eravacycline, severe infections) | Approximately 10% (inferred) | Not separately disclosed | Supply constrained (tight CDMO capacity; approximately RMB 150 million less shipped in H1) | In-hospital treatment of severe infections, with synergies with Haisen's acute and critical-care products; NRDL negotiations in 2026H2 |
| Weishiping (维适平; etrasimod, UC) | Initial stage | Not separately disclosed | First prescription issued upon approval in 2026-02 | New oral autoimmune therapy, viewed as a potential second growth curve; volume growth depends on NRDL negotiations |
| Haisen CSO service fees (connected party) | 12.6% (RMB 145 million) | Service-fee model | New contribution | Connected-party revenue sharing (20-55%); proposed transition to general distribution and gross revenue recognition |
| Xingbituo/Leruibo/in-house pipeline | — | — | Registration/pre-launch stage | Option value; see the pipeline section |
Main profit-generating segment: Nefecon. Based on its approximately 77-89% revenue share and the gross-profit structure of reimbursed products, Nefecon is inferred to contribute the overwhelming majority of gross profit; the company does not disclose gross profit by product, so this is a structural inference. FY2025 Nefecon sales exceeded RMB 1 billion (the company's stated lower bound), or approximately RMB 1.44 billion according to media estimates, representing 58.6%-84% of total revenue. Risk reminder: product-level gross margins are not disclosed, and reliance on a single product for the bulk of profit is itself the risk identified in C3. Differences in gross-margin structure cannot be calculated because the company discloses only consolidated figures; this is itself a weakness in disclosure quality. The business is clearly concentrated around "Nefecon plus a commercialization platform," while the other assets have yet to deliver.
Accounting red flags (by severity):
Consistency across periods: intangible-asset impairment was recognized in three consecutive years while being described as "one-off" each year—inconsistent. Operating cash flow remained negative, narrowing to RMB -93 million in 2025 before widening again in 2026H1 because of working capital—consistent with management's explanation. A single customer's share rose from 73.1% to 98.6% and then 98.0%—the company did not explain this. Borrowings increased from RMB 23 million to RMB 867 million and then RMB 1,921 million over one and a half years—consistent with management's explanation that the financing funded the Haisen acquisition; the loans are secured by EverSea equity. Overall, there is no observed evidence of accounting engineering at the revenue-recognition level: all receivables are within three months and impairment is minimal. The concerns center on how profit is presented and how impairments are described.
Current market data: share price HKD 27.02 (2026-11-06 close), market capitalization HKD 9.578 billion (approximately RMB 8.15 billion), and a 52-week range of HKD 22.70-50.30. The current price sits at the 15.7% percentile of that range; the high includes the 8-20 sentiment spike, so this positioning is only a reference. PE(TTM) is not meaningful: IFRS profit attributable to shareholders is close to break-even, and TTM earnings include substantial non-recurring items. PS(FY2025) is 4.78x versus a peer median of approximately 10.1x, about 53% lower. PS(FY2026E), based on this report's revenue forecast of RMB 3.95 billion including a one-time licensing payment of RMB 750 million, is approximately 2.1x, or approximately 2.6x after excluding the one-time item. PB is 1.56x; its denominator has been reduced by accumulated losses and is only a reference. FY2027E forward PE is approximately 10.2-16.3x, based on this report's attributable net-profit forecast of RMB 500-800 million, implying a PEG of approximately 0.3-0.4 against 37% revenue growth. The low earnings base makes this a cross-check rather than a primary valuation anchor. Liquidity is normal: average daily turnover over the past 30 days is approximately HKD 166 million, or about 1.7% of market capitalization, far above the 0.1% warning threshold. There is no low-liquidity discount issue.
Market-implied expectations: reverse valuation indicates that the current price roughly reflects a combination of "Nefecon peak sales of RMB 2.8-5.0 billion plus second-line pipeline assets valued at 50%-100% of their baseline value." If the second-line pipeline receives full baseline value, the current price supports Nefecon peak sales of only approximately RMB 2.8 billion—effectively peaking in 2026. If Nefecon receives the sell-side peak-sales assumption of RMB 5 billion in full, the second-line assets receive only half their baseline value. The market is materially more pessimistic than the sell side's HKD 40.5-66 range, with disagreement centered on the shape of peak sales after 2027 reimbursement-renewal price cuts and generic competition. A two-way demand-side arithmetic check: annual treatment costs at the reimbursement price are approximately RMB 24,000-25,000; baseline peak sales of RMB 3.8 billion imply about 155,000 patient-years of treatment, or 12% penetration of the approximately 1.3 million reachable diagnosed patients. The sell-side RMB 5 billion assumption implies approximately 15.7% penetration, while the bear-case RMB 2.2 billion implies approximately 7%, around the midpoint of 2026 guidance. There is genuine room for penetration to rise from 2% to 12%, supported by preferred positioning in guidelines, improved diagnosis rates and the Gd-IgA1 assay funnel. However, competing products are simultaneously dividing the addressable market. The current price represents fair pricing of the direction in which peak-sales expectations will converge, rather than deep undervaluation.
Three layers of value: net cash is approximately RMB +40 million, equivalent to about HKD 0.12 per share. The asset floor is book net assets of HKD 17.33 per share, including RMB 3.41 billion in intangible assets and RMB 650 million in goodwill—core operating assets for a biotech company, but sensitive to impairment. The premium of the HKD 27.02 share price over this floor, and indeed almost all of the valuation, rests on pipeline cash flows; growth options account for an extremely high proportion, approximately 99%. For a biotech company that has not reached sustainable profitability, there is no reliable base period for a zero-growth EPV estimate: 2026H1 recurring earnings were RMB -65 million and OCF was RMB -273 million. This report therefore uses rNPV/SOTP rather than forcing an EPV calculation (see the pipeline section). A high proportion of growth-option value does not, by itself, establish that the stock is expensive or cheap; the judgment depends on peak-sales assumptions and delivery of the ramp-up.
Three scenarios and risk-reward (absolute valuation is detailed in the rNPV/SOTP analysis in Section XI; this is the risk-reward framework):
| Scenario | Probability | Fair-value range (HKD) | Versus current price | Decisive factors |
|---|---|---|---|---|
| Bear | 30% | 11.5-13.5 | -53% (midpoint) | Renewal price cuts of 30-40% plus competitor diversion cap peak sales at approximately RMB 2.2 billion; Xingbituo fails in the self-pay market; aggregate rNPV RMB 3.8 billion |
| Base | 50% | 29-32.5 | +14% (midpoint) | Peak sales of RMB 3.8 billion, with volume growth offsetting renewal price cuts of 15-25%; ramp-up after successful NRDL negotiations; half of EVER001's potential realized; rNPV RMB 9.3 billion |
| Bull | 20% | 52-60 | +107% (midpoint) | Peak sales of RMB 5 billion; all three new drugs enter reimbursement in 2027; overseas mRNA BD; rNPV RMB 16.97 billion |
Probability-weighted fair value is approximately HKD 30.33 (+12.2%). Expected upside is positive, but asymmetric risk is substantial: the 30%-probability bear case implies a 53% loss, while the 20%-probability bull case implies 107% upside. The current price lies between the bear and base cases, closer to the base case. External-anchor comparison: even the most conservative named sell-side analyst, BOCOM, with a reduced target of HKD 66 and a Buy rating, is far above the lower end of this report's bull range. This difference reflects this report's Nefecon peak-sales assumption of RMB 3.8 billion, approximately 24% below the sell-side RMB 5 billion assumption, and its allocation of only RMB 400 million in option value to the mRNA platform. That sell-side anchor is undergoing downward revisions, reducing its usefulness as a reference.
This report's earnings forecasts (anchors for checking subsequent results):
| Period | Revenue (RMB 100 million) | Attributable net profit (RMB 100 million) | Key drivers |
|---|---|---|---|
| FY2026E | 38-41 (base 39.5, +131%) | 3.5-5.5 (including approximately 7.5 in one-time EVER001 upfront revenue; recurring profit approximately 0.5-1.5) | Nefecon 24-26 + Haisen service fees 3.5-4 + other products 3.0-3.6 + upfront payment 7.5, all in RMB 100 million |
| FY2027E | 50-58 (base 54, +37%) | 5-8 (net margin 9-15%) | Nefecon 30-35, assuming renewal price cuts of 15-25%; first-year Xingbituo sales 6-10; Weishiping 5-8, assuming successful NRDL negotiations; amounts in RMB 100 million |
Comparison with the sell side: this report's FY2026E revenue is slightly above SDIC's RMB 3.76 billion and Western Securities' RMB 3.435 billion, mainly because of differences in upfront-payment recognition. FY2027E is close to SDIC's RMB 5 billion estimate. Management has provided no total-revenue guidance; its Nefecon guidance is RMB 2.4-2.6 billion. Risk: if the EVER001 upfront payment is recognized over time rather than immediately, FY2026 revenue and profit will be below the table's forecasts.
Conclusion: toward the lower end of fair value, target price HKD 29-32.5, and approximately +7.3% margin of safety. Quality—a rapidly improving biotech company with strong execution—and price—toward the lower end of fair value, but without a deep discount—should be assessed separately. The base-case exit valuation is cross-checked using peak net profit of approximately RMB 1.06 billion multiplied by a steady-state earnings multiple of 12-16x for mature Chinese innovative-drug companies, consistent with this report's rNPV. The company's current trading multiple is not used as the anchor. The condition for adding exposure is successful NRDL negotiations plus H2 volume delivery that raises confidence in RMB 3.8 billion peak sales; the condition for avoiding exposure is larger-than-expected renewal price cuts and faster-than-expected competitor access.
Market size: China's innovative drug market was approximately RMB 1.13 trillion in 2024 and is expected to exceed RMB 1.3 trillion in 2026 (Frost & Sullivan/Cnhealthmedia figures; an alternative estimate puts it at USD 159.2 billion in 2024, potentially surpassing USD 300 billion by 2030, per China Pharmaceutical News), with recent growth of roughly 8-10% per year. Breaking down to Everest's core indications: ① IgA nephropathy — approximately 4-5 million patients in China (company figure), with diagnosed/existing patients around 750,000-1.3 million (CICC/Guosen/company figures vary); before 2025 there were virtually no disease-modifying drugs available, and the treatment market is in a zero-to-one explosive growth phase: Nefecon's first year on the National Reimbursement Drug List (NRDL) exceeded RMB 1 billion in sales (the first non-oncology product of its kind); CICC's 2023 estimate put China's IgAN market at RMB 4.05-9.24 billion by 2033, and sell-side peak sales forecasts for Nefecon in China range from RMB 2.4-5 billion — estimates vary widely but point in the same direction: penetration starting at 2-6%, with the ceiling determined by competition and payment; ② PSVT — prevalence of 2.25-4‰, roughly 3-6 million patients; etripamil is the first and only approved innovative therapy in over 30 years (FDA Dec 2025, NMPA Sep 2026), with no precedent for pricing and no competing mechanism of action; ③ UC (ulcerative colitis) — estimated 920,000-1.5 million patients in China by 2030; next-generation oral S1P modulators represent a supply vacuum; ④ PCSK9/high cholesterol — approximately RMB 3 billion in China in 2024, expected to reach RMB 10 billion by 2030 (Frost & Sullivan), but with 5 monoclonal antibodies plus 1 siRNA already approved, it is a red ocean.
Value chain and value distribution: The upstream comprises innovative molecules and clinical data from global biotechs/MNCs (Everest's license-in sources: Asahi Kasei, Pfizer, Milestone/Fast-Tracking Pharmaceuticals, LIB Therapeutics, Xinnovi, etc.), with fierce bidding for quality assets (global IgAN asset M&A exceeded USD 11.4 billion in 2024); the midstream is clinical development → registration → localized manufacturing (Everest's Jiashan GMP plant begins domestic production of Exblifep in 2027 to cut costs, leaving room for NRDL price negotiations); the downstream is specialist channels in tiered hospitals (nephrology/cardiology/GI) plus retail/online (JD Health partnership), with ultimate payers being basic medical insurance (negotiated products trade price for volume, average price cut of 63% in 2025) + the Commercial Insurance Innovative Drug List (first edition covered 19 products, already accessible at 1,486 designated institutions by 2026) + self-pay. Value (gross margin) accrues mainly to the commercialization stage: Everest's FY2025 gross margin was 69.3%, higher than pure profit-sharing models but below fully in-house R&D leaders (Innovent 86.5%) — the license-in model cedes upstream molecule value in exchange for certainty. Bargaining power over upstream is moderately strong (L Catterton ecosystem + China clinical asset repricing power; the return of Zaldiar to Gilead in 2024 for USD 455 million consideration is a classic example); bargaining power over downstream depends on exclusivity — Nefecon has strong bargaining power as the only NRDL-covered disease-modifying drug during its exclusivity window, weakening as competitors enter.
Supply-demand and competitive structure: Demand is driven by three factors — aging (CKD population exceeds 120 million), clinical guideline updates (the 2025 Chinese IgAN guidelines list Nefecon as the preferred disease-modifying therapy), and payment expansion (149 innovative drugs have entered the NRDL since 2018, driving over RMB 600 billion in sales during agreement periods). Rapid supply influx is the main tension: globally 5 IgAN drugs are approved, with 3-4 on sale in China + 2 filed + 2 global Phase III trials imminent (Zai Lab's Pove, positive proteinuria data due Mar 2026; atarsceptrin PDUFA Jul 2026); Novartis' atrasentan cut its Sichuan price by 53% in Jun 2026 ahead of the NRDL talks, signaling overt price competition. Concentration: Nefecon currently holds 100% of the NRDL payment channel in the IgAN innovative drug market (the only reimbursed product), but will face dilution from five competing pathways in 2027-2028; PSVT is exclusive supply (no competing mechanism); PCSK9 is a CR5+ red ocean. Entry barriers: 3-5 year cycles for renal hard-endpoint Phase III trials, NRDL access plus hospital listing speed, specialist channel building — precisely Everest's strengths. Substitution threats: radiofrequency ablation for PSVT (RMB 20,000-80,000 per procedure, potentially curative) is the long-term substitute for Etripamil; SGLT2/RAS basic therapy for IgAN is the low-cost baseline.
Cyclicality and regulation: The industry is in "mid-growth phase + early stage of an upcycle": after the Hong Kong innovative drug index rose 72% in 2025, it pulled back in 2026H1 and is recovering in the interim results season (A+H innovative drug 2026H1 revenue +21.3%, net profit attributable to shareholders +88.8%, Soochow Securities); financing has shifted from "funding-driven" to "global partnership-driven" — in 2025, 157 license-out deals totaling USD 135.7 billion (+161%), with upfront payments accounting for 52% of industry funding, exceeding equity financing for the first time — the industry soil for the EVER001 model. Policy is broadly favorable with localized price pressure: the Jul 2025 "Several Measures to Support High-Quality Development of Innovative Drugs" established full-chain support and the Commercial Insurance Innovative Drug List (Class C); the 2026 list adjustment has begun (601 NRDL products + 58 commercial insurance products passed formal review, results to be announced in November); the 63% average NRDL price cut and competitor pre-emptive price cuts cap single-product price ceilings. Everest's strategy (NRDL negotiation in the first year of launch + localized manufacturing to leave negotiation room) is aligned with policy direction.
Peer benchmarking (market cap as of 2026-11-06, revenue FY2025):
| Company | Market cap/Revenue | Revenue growth | Gross margin | Profitability | Core difference vs. Everest |
|---|---|---|---|---|---|
| Everest Medicines | RMB 8.15 bn/RMB 1.707 bn | +141.5% | 69.3% | Adjusted +RMB 187 mn (incl. one-offs) | Non-oncology blue-ocean differentiation + license-in self-commercialization |
| Innovent Biologics | ~7.6x Everest/RMB 13.04 bn | +38.4% | 86.5% | First IFRS profit of RMB 814 mn | Tier-1 fully in-house oncology + CVM |
| Akeso Biopharma | /RMB 3.056 bn | +43.9% | ~79% | Net loss RMB 1.141 bn (dragged by Summit) | Global rights out-licensing of bispecifics (ivonescimab) |
| RemeGen | /RMB 3.251 bn | +89.4% | Not obtained | Turnaround (incl. licensing revenue; core only RMB 65 mn) | Direct IgAN competitor (telitacicept) + ADC |
| Zai Lab | /~RMB 3.3 bn | +15% | Not obtained | Still loss-making | Also license-in self-commercialization, focused on autoimmune/oncology |
Company positioning: A differentiated mid-cap non-oncology player in the HK 18A "profitable (adjusted basis) Biotech tier-1" cohort — profitability realized earlier than Akeso/Zai Lab, revenue about 13% of Innovent's; share trend: Nefecon holds an absolute share of China's IgAN innovative drug market (only NRDL product), but share dilution in 2027-2028 is the base-case assumption; moat sources: nephrology/cardiology specialist channels and the A2MS omnichannel system, NRDL/commercial insurance access execution, localized GMP capacity, and L Catterton's BD network. Basis caveat: the company's self-description as a "profitable Biotech" refers to the adjusted basis; on an IFRS basis it is still loss-making (FY2025 -RMB 298 mn), and both bases must be presented side by side. Industry-positioning basis differences: the company cites KDIGO/Chinese guidelines listing Nefecon as preferred disease-modifying therapy (medical basis), while end-market share and competitive data have no independent third-party audited basis; sell-side estimates are flagged where cited.
| Asset | Indication | Stage | Source/Rights | Key terms/Notes |
|---|---|---|---|---|
| Nefecon | IgA nephropathy | Marketed (approved Nov 2023, NRDL Jan 2025) | license-in Asahi Kasei, Greater China + Korea + Singapore | Second NRDL year; FY2026 guidance RMB 2.4-2.6 bn |
| Exblifep (ceftazidime-avibactam) | cIAI severe infections | Marketed | license-in Innoviva | NRDL talks 2026H2; CDMO supply tight |
| Velsipity (etrasimod) | UC | Marketed (Feb 2026) | license-in Pfizer | NRDL talks 2026H2 |
| NEFECON/Etripamil nasal spray | PSVT acute episodes | Marketed (Sep 3, 2026) | Acquisition of Fast-Tracking assets (≤USD 50 mn) | Acquisition upfront USD 30 mn + USD 20 mn milestones |
| Milatuzumab? MIL62 (CD20) | NMOSD/PMN | Marketed (Feb/Jun 2026, APAC rights) | license-in Genor Biopharma | Southeast Asia/India/Korea-Australia-NZ/HK-Macau-Taiwan |
| Lerilimab? Recatolimab (lenalespath?) | Hypercholesterolemia | China BLA accepted (Jun 2026) | license-in Hisen/LIB | Upfront USD 29 mn + milestones |
| EVER001 (Xibutitinib? , BTK) | pMN/IgAN/FSGS etc. | Phase II | Co-development (Xinnovi), global rights | Out-licensed to Travere (ex-Greater China etc.): upfront USD 112.5 mn + milestones ≤USD 1.03 bn + royalties |
| MT1013 | SHPT | China Phase III (enrollment completed Apr 2026) | license-in Mettaifeite? (Feb 2026) | R&D costs borne by partner |
| DMX-200 | FSGS | Global Phase III ACTION3 | license-in Dimerix (Jun 2026) | Greater China + Korea + Southeast Asia rights |
| Vicagrel | ACS | pre-NDA | license-in Vicaire? | APAC rights |
| Cefepime-taniborbactam | cUTI | China pre-NDA | license-in Venatorx | Partner has suspended operations; risky asset |
| VIS-101 (VEGF-A/ANG-2) | Wet AMD | Phase II (IIb planned 2026H2) | license-in Visara | Upfront USD 7 mn |
| LNZ100 (aceclidine) | Presbyopia | China NDA (submitted Sep 2025) | Acquisition of Fast-Tracking/LENZ rights | Approval expected 2027H1 |
| EVM16 | Personalized mRNA cancer vaccine | IIT Ib planned 2026Q4 | In-house, global rights | FIH data Apr 2026 AACR |
| EVM14 | Off-the-shelf TAA vaccine | Phase I, dual IND China-US | In-house | Dose escalation delayed to 2027Q1 |
| EVM18 | mRNA in-vivo CAR-T | Autoimmune IIT launched, global IND planned 2026H2 | In-house | Platform option |
Structural feature: all commercialization and late-registration assets are license-in/acquired (in-house assets all early-stage) — pipeline value depends heavily on "acquisition acumen + commercialization execution," while the in-house mRNA platform is pure option value.
Method: per-asset rNPV = peak sales × net margin × annuity factor (12% discount) × PoS (probability of success), summed + net cash, converted per share at HKD 1 = RMB 0.851 and 354.5 mn shares (unit: RMB 100 mn):
| Asset | Bear | Base | Bull | Key base-case assumptions |
|---|---|---|---|---|
| Nefecon | 15.8 | 42.1 | 76.0 | Peak RMB 2.2/3.8/5.0 bn; net margin 24-32%; PoS 0.75-0.95 |
| Etripamil nasal spray | 4.4 | 10.5 | 18.7 | Peak RMB 0.8/1.5/2.2 bn; PoS 0.55-0.85 |
| Velsipity | 4.2 | 7.4 | 13.4 | Peak RMB 0.8/1.2/1.8 bn; PoS 0.60-0.85 |
| Exblifep | 1.7 | 2.5 | 3.8 | Peak RMB 0.3/0.45/0.6 bn |
| Recatolimab | 1.7 | 3.3 | 6.1 | Peak RMB 0.5/0.8/1.2 bn (PCSK9 red ocean price pressure) |
| EVER001 (milestones + royalty net) | 3.0 | 9.0 | 16.0 | Travere peak USD 0.4-0.6 bn × ~10% royalty |
| MT1013 | 1.8 | 3.4 | 5.4 | Peak RMB 0.4/0.6/0.8 bn |
| Other early-stage portfolio (DMX-200/LNZ100/Vicagrel/MIL62/VIS-101) | 1.5 | 3.5 | 6.0 | PoS-weighted low values |
| In-house mRNA platform | 0.5 | 4.0 | 12.0 | Pure option; bull case corresponds to one out-licensing BD |
| Hisen service fee stream + APAC platform | 3.0 | 7.0 | 12.0 | Service net margin 30-35% |
| Net cash | 0.4 | 0.4 | 0.4 | Incl. tail-payment deductions |
| SOTP total | 38.0 | 93.0 | 169.7 | — |
| Per share (HKD) | 12.6 | 30.8 | 56.2 | Current price 27.02 |
Sensitivity: Nefecon peak -30% (RMB 2.66 bn) → HKD 26.63 per share; +30% (RMB 4.94 bn) → 35.01; PoS 0.88→0.75 → 28.76; 0.88→0.95 → 31.93. Conclusion: the current price roughly prices in 88% of the base case — not deeply undervalued; sensitivity to the single variable of Nefecon (±30% peak ≈ ±HKD 4-5 per share) is smaller than sensitivity to the qualitative view on competitive structure (bear/bull spread of HKD 43.6).
| Timing | Event | Directional impact |
|---|---|---|
| 2026-11-16 | EGM vote on Hisen framework agreement | Approval mildly neutral; rejection -8~-12% |
| Late Nov 2026 | NRDL results (Velsipity/Exblifep access + Nefecon renewal + commercial insurance list) | Both wins +10-20%; both losses -15~-25% |
| Dec 2026–Mar 2027 | Etripamil launch ramp + Gd-IgA1 test kit approval | +2~+10% |
| 2026Q4-2027Q2 | mRNA four milestones (EVM16 Ib start/EVM18 IND/EVM20 PCC/EVM14 escalation) | Per milestone +3~8%; positive Ib data +10-20% |
| Mar 2027 | FY2026 annual report (verification of Nefecon RMB 2.4 bn floor) | Met +5-15%; miss -15~-20% |
| 2027-Q2 | Recatolimab approval expected | +5-10% |
| 2027 | DMX-200 global Phase III topline (FSGS) | Success +15-30%; failure -10-15% |
| 2027-H2 | MT1013 China Phase III topline (SHPT) | Success +15-30%; failure -10-20% |
| Around 2027 | mRNA platform BD (unconfirmed, MNCs in talks) | Deal signed +20-40% |
Cash + deposits of RMB 1.859 bn at 2026-06-30 (plus FVTPL RMB 177 mn) + approximately RMB 750 mn from the July EVER001 upfront vs. interest-bearing borrowings of RMB 1.921 bn + approximately RMB 650 mn Hisen tail payment — net cash approximately +RMB 40 mn. Annualizing 2026H1 operating burn (approx. RMB 550 mn/year) + average annual CapEx of approx. RMB 120 mn + license payments and acquisition tail payments, the runway is approximately 2.5-3 years; no survival risk within 12-18 months, but the remaining RMB 1.041 bn (HKD equivalent) from the Aug 2025 placement is planned to be spent by 2027H2, and the "3-5 blockbusters introduced per year" strategy implies a high probability of refinancing in 2027-2028 — the current price is 61% below the Aug 2025 placement price of HKD 69.7, meaning an equally sized raise would require roughly 3x more shares issued; dilutive refinancing at depressed prices (potentially 15-20%) is a foreseeable medium-term risk; 20.8 mn unexercised options (strike HKD 10.08-22.54) + the 10% cap of the 2026 share plan constitute a continuing SBC dilution channel.
Nefecon: the world's first and only same-mechanism IgAN disease-modifying (gut mucosal immune-targeted) drug, with US orphan drug exclusivity through Dec 2030; across mechanisms, 5 drugs are approved globally, and the proteinuria reductions of Pove/sibeprenlimab (~-50%) are numerically higher than Nefecon's — long-term competitive standing under pressure; short-term positioning relies on "only NRDL product + guideline-preferred + oral." Etripamil nasal spray: the only approved innovative drug worldwide for acute PSVT (zero same-mechanism competitors); the substitution threat is radiofrequency ablation, not drugs. Recatolimab: third-generation PCSK9, once-monthly injection + room-temperature stable, but 5 domestic monoclonal antibodies + siRNA are first movers and already reimbursed — a latecomer in a red ocean, able to differentiate only via NRDL talks and channels. EVER001: positive 52-week Ib/IIa data in pMN; Travere takes over global development (ex-Greater China etc.); MNC partner endorsement confirms its value; the leading global position among BTK class drugs in nephrology.
Overall rating: Neutral, confidence 0.50, 12-month horizon. Everest is a non-oncology Biotech with leading execution among 18A companies: a good execution track record (nearly all three-year commitments delivered), genuine barriers in channels and market access, and a dense wave of second-tier assets entering monetization windows; but the current price offers only +14% headroom to base-case fair value, the safety margin of +7.3% is under 10%, and the bear case with 30% probability (renewal price cut + competitive diversion, -53%) is enough to swallow the gains from two successful events. Strategy: the NRDL results (late November) and FY2026 annual report (Mar 2027) are the two decisive validation points; chasing upside before they land is not advised; reassess direction if the price breaks below HKD 22.70 (52-week low, near and below L Catterton's recent purchase price of HKD 26.99) or above HKD 32.5 (upper bound of base-case fair value). Key risks: Nefecon peak falsification, deteriorating earnings quality (fair-value reversals + impairments), loss of control over L Catterton-related transactions, dilutive low-price refinancing. Key catalysts: NRDL double win, Etripamil ramp exceeding expectations, mRNA platform BD, EVER001 milestone realization, continued L Catterton accumulation.
This report is based on publicly available information as of 2026-11-07 (company announcements, earnings call transcripts, sell-side research, industry data); Nefecon product-level revenue and some competitor dynamics rely on sell-side/media accounts, flagged throughout; exchange rates HKD 1 = RMB 0.8514 and USD 1 = RMB 6.674 (2026-11-07). The price benchmark is the 2026-11-06 close of HKD 27.02, used consistently throughout.